• Explore /
  • Poster
  • / The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC).

The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC).

Abstract Poster

Authors

Martin Voss

Martin Henner Voss

Memorial Sloan Kettering Cancer Center, New York, NY

Martin Henner Voss , Elizabeth R. Plimack , Brian I. Rini , Michael B. Atkins , Robert Alter , Rupal Satish Bhatt , J. Thaddeus Beck , Musa Mutyaba , Kristen M. Pappas , Dawn Wilson , Xiaosha Zhang , Matthew L. Sherman , Shuchi Sumant Pandya

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT01727336

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4567)

DOI

10.1200/jco.2015.33.15_suppl.4567

Abstract #

4567

Poster Bd #

241

Abstract Disclosures

Similar Posters

First Author: Martin Henner Voss

First Author: Michael B. Atkins

First Author: Martin Henner Voss

First Author: Xingming Zhang